TIRZEPATIDE 60MG

Tirzepatide is a 39–amino acid dual incretin receptor agonist that activates both GLP‑1 and GIP receptors, enhancing glucose‑dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite. Its ~5‑day half‑life allows convenient once‑weekly subcutaneous dosing. Clinical trials demonstrate superior glycemic control and weight reduction compared to selective GLP‑1 agonists^.

• Reconstitute: Add 3.0 mL bacteriostatic water → 20.0 mg/mL concentration.

• Typical weekly range: 2.5–15 mg once weekly (gradual 4‑week titration steps).

  
  

• Easy measuring: At 10.0 mg/mL, 1 unit = 0.01 mL = 100 mcg on a U‑100 insulin syringe.

  
  

• Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); use within 28 days.